Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 141
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 116
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 103
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 88
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 76
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 46
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 2, pp. 311-322
Closed Access | Times Cited: 22
Targeted protein degradation directly engaging lysosomes or proteasomes
Jiseong Kim, Insuk Byun, Do Young Kim, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 7, pp. 3253-3272
Open Access | Times Cited: 21
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 14
PROTAC-induced Protein Structural Dynamics in Targeted Protein Degradation
Kingsley Y Wu, Ta I Hung, Chia‐en A. Chang
(2025)
Open Access | Times Cited: 1
Fluorinated Cycloalkyl Building Blocks for Drug Discovery
Oleksandr O. Grygorenko, Kostiantyn P. Melnykov, Serhii Holovach, et al.
ChemMedChem (2022) Vol. 17, Iss. 21
Closed Access | Times Cited: 57
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Cheung Hoi Yu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 52
Expanding the landscape of E3 ligases for targeted protein degradation
Luke T. Kramer, Xiaoyu Zhang
Current Research in Chemical Biology (2022) Vol. 2, pp. 100020-100020
Open Access | Times Cited: 46
Stereochemical diversity as a source of discovery in chemical biology
Kevin A. Scott, Nathalie Ropek, Bruno Melillo, et al.
Current Research in Chemical Biology (2022) Vol. 2, pp. 100028-100028
Open Access | Times Cited: 40
Formation of C(sp2)–C(sp3) Bonds Instead of Amide C–N Bonds from Carboxylic Acid and Amine Substrate Pools by Decarbonylative Cross-Electrophile Coupling
Jiang Wang, Lauren E. Ehehalt, Zhidao Huang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 18, pp. 9951-9958
Open Access | Times Cited: 34
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Kenneth K.W. To, Enming Xing, Ross C. Larue, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3043-3043
Open Access | Times Cited: 32
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 30
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology
Iacovos N. Michaelides, Gavin W. Collie
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3173-3194
Open Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
Arvind Negi, Anne Sophie Voisin‐Chiret
ChemBioChem (2022) Vol. 23, Iss. 12
Open Access | Times Cited: 34
A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs
Irene Preet Bhela, Alice Ranza, Federica Carolina Balestrero, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15282-15299
Open Access | Times Cited: 33
Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top